Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Pirtobrutinib in Combination with Rituximab for the Treatment of Untreated Marginal Zone Lymphoma, PIONEER Trial

Trial Status: active

This phase II trial studies how well pirtobrutinib in combination with rituximab works in treating patients with untreated marginal zone lymphoma. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals cancer cells to multiply. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving the combination of pirtobrutinib and rituximab may be a safe and effective treatment for patients with untreated marginal zone lymphoma.